^
Association details:
| Biomarker: | ER negative |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
Published date:
06/30/2022
Excerpt:
HER2-positive early BC patients given neoadjuvant chemotherapy with trastuzumab and pertuzumab...55 of 80 (71%) tumours were ER-positive. PCR occurred in 37 of 78 (46.3%; 95% CI: 35.3-57.2%) patients. 14 of 23 (60.8%) patients with ER-negative tumours achieved pCR; 23 of 55 (41.8%)...This data confirms the efficacy of neoadjuvant chemotherapy combined with dual HER2 directed therapy.
Secondary therapy:
Chemotherapy
DOI:
10.1155/2022/7146172
Source:
Title:
TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.
Published date:
05/16/2018
Excerpt:
The multicenter phase II TBCRC026 trial administered 4 cycles of neoadjuvant PT in women with stage II/III, ER-negative, HER2-positive BC (NCT01937117). pCR after PT alone was 34% (28/83). Percent reduction and D15 SULmax significantly differ between those with pCR versus not, after 4 cycles PT, in ER-negative/HER2-positive BC.
DOI:
10.1200/JCO.2018.36.15_suppl.511
Trial ID:
